menu
    • menu
    [{"orgOrder":0,"company":"University of Milan","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tobramycin","moa":"70S ribosome","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"University of Milan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Milan \/ Chiesi Group","highestDevelopmentStatusID":"11","companyTruncated":"University of Milan \/ Chiesi Group"},{"orgOrder":0,"company":"University of Milan","sponsor":"Regen Lab","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ITALY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"University of Milan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Milan \/ Regen Lab","highestDevelopmentStatusID":"11","companyTruncated":"University of Milan \/ Regen Lab"},{"orgOrder":0,"company":"University of Milan","sponsor":"BMG Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydrogen Peroxide","moa":"PTPN1 messenger RNA (PTPN1 mRNA)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"University of Milan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"University of Milan \/ BMG Pharma","highestDevelopmentStatusID":"10","companyTruncated":"University of Milan \/ BMG Pharma"},{"orgOrder":0,"company":"University of Milan","sponsor":"BMG Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydrogen Peroxide","moa":"PTPN1 messenger RNA (PTPN1 mRNA)","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"University of Milan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"University of Milan \/ BMG Pharma","highestDevelopmentStatusID":"10","companyTruncated":"University of Milan \/ BMG Pharma"},{"orgOrder":0,"company":"University of Milan","sponsor":"Azienda Farmaceutica Italiana","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Polaprezinc","moa":"Tumor necrosis factor; Interleukin-6; Interleukin-3; Vascular endothelial growth factor receptor 1; Beta-nerve growth factor; Platelet-derived growth factor receptor beta; Heat shock protein HSP 90-alpha; Heat shock protein HSP 90-beta","graph1":"Neurology","graph2":"Phase III","graph3":"University of Milan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"University of Milan \/ Azienda Farmaceutica Italiana","highestDevelopmentStatusID":"10","companyTruncated":"University of Milan \/ Azienda Farmaceutica Italiana"}]

    Find Clinical Drug Pipeline Developments & Deals by University of Milan

    Menu

    University of Milan

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University of Milan

                            Italy arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University of Milan

                            Italy arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrogen Peroxide

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase III

                            Sponsor : BMG Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of a Hydrogen-Peroxide and Hyaluronic-Acid Mouthwash (BMG0703) in the Treatment of Periodontitis

                            Details : Hydrogen Peroxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Periodontitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 25, 2020

                            Lead Product(s) : Hydrogen Peroxide

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase III

                            Sponsor : BMG Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University of Milan

                            Italy arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University of Milan

                            Italy arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrogen Peroxide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : BMG Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Hydrogen Peroxide and Hyaluronic Acid (BMG0703) in the Healing of Post-extraction Sites

                            Details : Hydrogen Peroxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Wound Healing.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 18, 2020

                            Lead Product(s) : Hydrogen Peroxide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : BMG Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University of Milan

                            Italy arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University of Milan

                            Italy arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polaprezinc

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Azienda Farmaceutica Italiana

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Zinc L-Carnosine Mouth Rinse

                            Details : Zinc L-Carnosine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            June 16, 2020

                            Lead Product(s) : Polaprezinc

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Azienda Farmaceutica Italiana

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            University of Milan

                            Italy arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University of Milan

                            Italy arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Regen Lab

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Hyaluronic Acid and Platelet-rich Plasma Combination in Knee Osteoarthritis

                            Details : Hyaluronic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 07, 2017

                            Lead Product(s) : Hyaluronic Acid

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Regen Lab

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            University of Milan

                            Italy arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University of Milan

                            Italy arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tobramycin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase IV

                            Sponsor : Chiesi Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis

                            Details : Tobramycin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cystic Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            May 31, 2012

                            Lead Product(s) : Tobramycin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase IV

                            Sponsor : Chiesi Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth